Stephen Lobue, MD
Ophthalmology · Murrieta, CANPI 1245735984
Payments from drug & device makers
Across 121 payments — averaging $118.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$9K
- Alcon$2K
- Rxsight Inc$2K
- Sight Sciences, Inc.$648
- NEW World Medical,inc.$332
- Bausch & Lomb Americas Inc.$242
- plus $838 from 10 others
What the payments were for
- Consulting fees$7,80055%
- Travel & lodging$4163%
- Food & beverage$6,07443%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 27 | $8,890 |
| Alcon | 52 | $1,817 |
| Rxsight Inc | 11 | $1,523 |
| Sight Sciences, Inc. | 5 | $648 |
| NEW World Medical,inc. | 2 | $332 |
| Bausch & Lomb Americas Inc. | 3 | $242 |
| Ocular Therapeutix, Inc. | 2 | $167 |
| Dompe US, Inc. | 2 | $151 |
| Harrow Eye, LLC | 3 | $144 |
| Oyster Point Pharma, Inc. | 5 | $101 |
| Novartis | 3 | $92 |
| Tarsus Pharmaceuticals, Inc. | 1 | $75 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
| AbbVie | 2 | $31 |
| Amgen | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Travoprost Intraocular Implant - iDose$6,389
- RXSIGHT CONTACT LENS$1,200
- RXSIGHT INJECTOR CARTRIDGE$1,200
- LIGHT ADJUSTABLE LENS (LAL)$1,200
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,200
- RXSIGHT INJECTOR HANDPIECE$1,200
- iDose$1,121
- OMNI(R) SURGICAL SYSTEM (US)$510
- iDoseTR$355
- NGENUITY$323
- Hydrus Microstent$149
- DEXTENZA$148
- Clareon PanOptix Pro$145
- Photrexa Viscous and Photrexa$144
- KXL System$144
- SION SURGICAL INSTRUMENT$140
- iStent Infinite$134
- CE-marked KXLA system$134
- Oxervate$118
- enVista MX60 IOL$116
How this compares
$14,290 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 72 | $48,004 |
| Prednisolone Acetate | 591 | $14,126 |
| LumiganBimatoprost | 22 | $13,527 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $12,575 |
| MoxifloxacinMoxifloxacin Hcl | 573 | $11,806 |
| Cyclosporine | 43 | $11,168 |
| Ketorolac Tromethamine | 519 | $8,159 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,004 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $3,347 |
| Latanoprost | 372 | $2,714 |
| ErythromycinErythromycin Base | 206 | $2,240 |
| Brimonidine Tartrate | 122 | $2,127 |
| Atropine Sulfate | 69 | $2,002 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 92 | $1,911 |
| Timolol Maleate | 168 | $1,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $31 | $61,53194 claims |
| AlconSimbrinza | $1,817 | $4,00420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Murrieta
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.